{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:29:36Z","timestamp":1726763376760},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Hypertonie ist eine sehr h\u00e4ufige Komorbidit\u00e4t bei Patient:innen mit Diabetes mellitus, die \u2013\u00a0wenn unzureichend behandelt\u00a0\u2013 signifikant zur erh\u00f6hten Mortalit\u00e4t und zum Auftreten von mikrovaskul\u00e4ren und makrovaskul\u00e4ren Komplikationen beitr\u00e4gt. Eine Individualisierung der Blutdruckzielwerte in Abh\u00e4ngigkeit vom Patient:innenalter und vom Vorliegen bestimmter vaskul\u00e4rer Komplikationen wird heute weltweit diskutiert. Blutdruckzielwerte um 130\/80\u202fmm Hg waren in den Studien mit der geringsten Ereignisrate an Komplikationen assoziiert, wobei die Blutdruckzielwerte je nach Alter und Komorbidit\u00e4ten individualisiert werden sollten; am wichtigsten ist f\u00fcr die meisten Patient:innen, dass ein Blutdruck &lt;\u202f140\/90\u202fmm Hg erreicht wird. ACE-Hemmer oder Angiotensin-Rezeptorblocker sollen in der Hypertonie-Therapie bei Patient:innen mit Diabetes mellitus bevorzugt werden, vor allem wenn Albuminurie oder KHK vorliegen. F\u00fcr die meisten Patient:innen mit Diabetes ist eine Kombinationstherapie notwendig, wobei Medikamente mit nachgewiesenem kardiovaskul\u00e4rem Nutzen (neben ACE-Hemmern und altenativ Angiotensin-Rezeptorblockern, Dihydropyridin-Calciumantagonisten und Thiazid-Diuretika) eingesetzt werden sollten, pr\u00e4ferentiell als Kombinationspr\u00e4parate. Nach Erreichung der Zielwerte muss die antihypertensive Therapie fortgef\u00fchrt werden, wobei regelm\u00e4\u00dfige Blutdruckmessungen durch die Patient:innen f\u00fcr die Optimierung der Blutdruckeinstellung sehr hilfreich sind. Neuere Antidiabetika wie SGLT2-Inhibitoren oder GLP1-Rezeptoragonisten tragen ebenfalls zur Blutdrucksenkung bei.<\/jats:p>","DOI":"10.1007\/s00508-023-02189-1","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:03:25Z","timestamp":1682550205000},"page":"147-156","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der \u00d6sterreichischen Diabetes Gesellschaft (Update 2023)","Individualising antihypertensive therapy in patients with diabetes. A\u00a0guideline by the Austrian Diabetes Association (update 2023)"],"prefix":"10.1007","volume":"135","author":[{"given":"Christoph H.","family":"Saely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Klauser-Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guntram","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"19","key":"2189_CR1","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton\u00a0PK, Carey\u00a0RM, Aronow\u00a0WS, Casey\u00a0DE Jr., Collins\u00a0KJ, Dennison Himmelfarb\u00a0C, et\u00a0al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. J\u00a0Am Coll Cardiol. 2018;71(19):e127\u2013e248.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2189_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMp1716193","volume":"378","author":"G Bakris","year":"2018","unstructured":"Bakris\u00a0G, Sorrentino\u00a0M. Redefining hypertension\u2014assessing the new blood-pressure guidelines. N\u00a0Engl J Med. 2018;378(6):497\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"2189_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jacc.2017.11.029","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli\u00a0FH, Bangalore\u00a0S. Lowering the thresholds of diseases: is anyone still healthy? J\u00a0Am Coll Cardiol. 2018;71(2):119\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2189_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00125-017-4537-3","volume":"61","author":"G Mancia","year":"2018","unstructured":"Mancia\u00a0G, Grassi\u00a0G. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. Diabetologia. 2018;61(3):517\u201325.","journal-title":"Diabetologia"},{"issue":"2","key":"2189_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00508-012-0270-6","volume":"124","author":"G Schernthaner","year":"2012","unstructured":"Schernthaner\u00a0G, Drexel\u00a0H, Rosenkranz\u00a0AR, Schernthaner\u00a0GH, Watschinger\u00a0B. Antihypertensive therapy in diabetes mellitus\u20142012 guidelines of the Austrian diabetes association. Wien Klin Wochenschr. 2012;124(2):23\u20137.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"2189_CR6","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1007\/s00508-015-0924-2","volume":"128","author":"G Schernthaner","year":"2016","unstructured":"Schernthaner\u00a0G, Drexel\u00a0H, Rosenkranz\u00a0A, Schernthaner\u00a0GH, Watschinger\u00a0B. Antihypertensive therapy in diabetes mellitus: guidelines of the Austrian diabetes association 2016. Wien Klin Wochenschr. 2016;128(2):S62\u20137.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"2189_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00508-019-1460-2","volume":"131","author":"G Schernthaner","year":"2019","unstructured":"Schernthaner\u00a0G, Saely\u00a0CH, Schernthaner\u00a0GH, Watschinger\u00a0B, Drexel\u00a0H. Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian diabetes association (update 2019). Wien Klin Wochenschr. 2019;131(1):124\u201335.","journal-title":"Wien Klin Wochenschr"},{"issue":"9841","key":"2189_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","volume":"380","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini\u00a0E, Cushman\u00a0WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601\u201310.","journal-title":"Lancet"},{"issue":"6","key":"2189_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/CIRCRESAHA.118.314487","volume":"124","author":"D Sun","year":"2019","unstructured":"Sun\u00a0D, Zhou\u00a0T, Heianza\u00a0Y, Li\u00a0X, Fan\u00a0M, Fonseca\u00a0VA, et\u00a0al. Type 2 diabetes and hypertension. Circ Res. 2019;124(6):930\u20137.","journal-title":"Circ Res"},{"issue":"7","key":"2189_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing\u00a0RR, Lang\u00a0W, Wadden\u00a0TA, Safford\u00a0M, Knowler\u00a0WC, Bertoni\u00a0AG, et\u00a0al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"2","key":"2189_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler\u00a0J, Vaccaro\u00a0O, Neaton\u00a0JD, Wentworth\u00a0D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434\u201344.","journal-title":"Diabetes Care"},{"issue":"7258","key":"2189_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","volume":"321","author":"AI Adler","year":"2000","unstructured":"Adler\u00a0AI, Stratton\u00a0IM, Neil\u00a0HA, Yudkin\u00a0JS, Matthews\u00a0DR, Cull\u00a0CA, et\u00a0al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412\u20139.","journal-title":"BMJ"},{"issue":"12","key":"2189_CR13","first-page":"1462","volume":"28","author":"G Mancia","year":"2007","unstructured":"Mancia\u00a0G, De Backer\u00a0G, Dominiczak\u00a0A, Cifkova\u00a0R, Fagard\u00a0R, Germano\u00a0G, et\u00a0al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart\u00a0J. 2007;28(12):1462\u2013536.","journal-title":"Eur Heart J"},{"issue":"11","key":"2189_CR14","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia\u00a0G, Laurent\u00a0S, Agabiti-Rosei\u00a0E, Ambrosioni\u00a0E, Burnier\u00a0M, Caulfield\u00a0MJ, et al. Reappraisal of European guidelines on hypertension management: a\u00a0European society of hypertension task force document. J\u00a0Hypertens. 2009;27(11):2121\u201358.","journal-title":"J Hypertens"},{"issue":"24","key":"2189_CR15","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1161\/CIRCULATIONAHA.111.033704","volume":"123","author":"PC Deedwania","year":"2011","unstructured":"Deedwania\u00a0PC. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? Circulation. 2011;123(24):2776\u20138.","journal-title":"Circulation"},{"issue":"2","key":"2189_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1751-7176.2011.00570.x","volume":"14","author":"M Garcia-Touza","year":"2012","unstructured":"Garcia-Touza\u00a0M, Sowers\u00a0JR. Evidence-based hypertension treatment in patients with diabetes. J\u00a0Clin Hypertens (Greenwich). 2012;14(2):97\u2013102.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"2189_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/157016112799304996","volume":"10","author":"RG Kalaitzidis","year":"2012","unstructured":"Kalaitzidis\u00a0RG, Bakris\u00a0GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10(2):156\u201361.","journal-title":"Curr Vasc Pharmacol"},{"issue":"17","key":"2189_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman\u00a0WC, Evans\u00a0GW, Byington\u00a0RP, Goff\u00a0DC Jr., Grimm\u00a0RH Jr., Cutler\u00a0JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N\u00a0Engl J Med. 2010;362(17):1575\u201385.","journal-title":"N Engl J Med"},{"issue":"12","key":"2189_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2337\/dc17-1366","volume":"40","author":"LF Buckley","year":"2017","unstructured":"Buckley\u00a0LF, Dixon\u00a0DL, Wohlford\u00a0GF, Wijesinghe\u00a0DS, Baker\u00a0WL, Van Tassell\u00a0BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care. 2017;40(12):1733\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"2189_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2337\/dc17-1722","volume":"41","author":"TF Brouwer","year":"2018","unstructured":"Brouwer\u00a0TF, Vehmeijer\u00a0JT, Kalkman\u00a0DN, Berger\u00a0WR, van den Born\u00a0BH, Peters\u00a0RJ, et\u00a0al. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care. 2018;41(6):1142\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"2189_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","volume":"53","author":"G Schernthaner","year":"2010","unstructured":"Schernthaner\u00a0G, Barnett\u00a0AH, Betteridge\u00a0DJ, Carmena\u00a0R, Ceriello\u00a0A, Charbonnel\u00a0B, et\u00a0al. Is the ADA\/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53(7):1258\u201369.","journal-title":"Diabetologia"},{"issue":"13","key":"2189_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.2018.0642","volume":"319","author":"IH de Boer","year":"2018","unstructured":"de Boer\u00a0IH, Bakris\u00a0G, Cannon\u00a0CP. Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC\/AHA recommendations. JAMA. 2018;319(13):1319\u201320.","journal-title":"JAMA"},{"issue":"1","key":"2189_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff\u00a0RM, Gong\u00a0Y, Handberg\u00a0EM, Bavry\u00a0AA, Denardo\u00a0SJ, Bakris\u00a0GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61\u20138.","journal-title":"JAMA"},{"issue":"1","key":"2189_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2337\/dc10-1420","volume":"34","author":"RJ Anderson","year":"2011","unstructured":"Anderson\u00a0RJ, Bahn\u00a0GD, Moritz\u00a0TE, Kaufman\u00a0D, Abraira\u00a0C, Duckworth\u00a0W. Blood pressure and cardiovascular disease risk in the veterans affairs diabetes trial. Diabetes Care. 2011;34(1):34\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"2189_CR25","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/dc22-S010","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(1):S144\u2013s74.","journal-title":"Diabetes Care"},{"issue":"5","key":"2189_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cjca.2015.02.016","volume":"31","author":"SS Daskalopoulou","year":"2015","unstructured":"Daskalopoulou\u00a0SS, Rabi\u00a0DM, Zarnke\u00a0KB, Dasgupta\u00a0K, Nerenberg\u00a0K, Cloutier\u00a0L, et\u00a0al. The 2015 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015;31(5):549\u201368.","journal-title":"Can J Cardiol"},{"issue":"4","key":"2189_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2014.20","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto\u00a0K, Ando\u00a0K, Fujita\u00a0T, Hasebe\u00a0N, Higaki\u00a0J, Horiuchi\u00a0M, et\u00a0al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37(4):253\u2013390.","journal-title":"Hypertens Res"},{"key":"2189_CR28","doi-asserted-by":"publisher","first-page":"d4891","DOI":"10.1136\/bmj.d4891","volume":"343","author":"T Krause","year":"2011","unstructured":"Krause\u00a0T, Lovibond\u00a0K, Caulfield\u00a0M, McCormack\u00a0T, Williams\u00a0B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.","journal-title":"BMJ"},{"issue":"34","key":"2189_CR29","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM, Carballo\u00a0D, Koskinas\u00a0KC, B\u00e4ck\u00a0M, et\u00a0al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart\u00a0J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"2","key":"2189_CR30","first-page":"6","volume":"61","author":"Association of Physicians of India","year":"2013","unstructured":"Association of Physicians of India. Indian guidelines on hypertension (I.G.H.)\u2014III. 2013. J\u00a0Assoc Physicians India. 2013;61(2):6\u201336.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"2189_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James\u00a0PA, Oparil\u00a0S, Carter\u00a0BL, Cushman\u00a0WC, Dennison-Himmelfarb\u00a0C, Handler\u00a0J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"issue":"22","key":"2189_CR32","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr.","year":"2015","unstructured":"Wright\u00a0JT Jr., Williamson\u00a0JD, Whelton\u00a0PK, Snyder\u00a0JK, Sink\u00a0KM, Rocco\u00a0MV, et al. A randomized trial of intensive versus standard blood-pressure control. N\u00a0Engl J Med. 2015;373(22):2103\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"2189_CR33","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2337\/dci17-0063","volume":"41","author":"JA Lamprea-Montealegre","year":"2018","unstructured":"Lamprea-Montealegre\u00a0JA, de Boer\u00a0IH. Reevaluating the evidence for blood pressure targets in type 2 diabetes. Diabetes Care. 2018;41(6):1132\u20133.","journal-title":"Diabetes Care"},{"issue":"6","key":"2189_CR34","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2337\/dc13-2334","volume":"37","author":"KL Margolis","year":"2014","unstructured":"Margolis\u00a0KL, O\u2019Connor\u00a0PJ, Morgan\u00a0TM, Buse\u00a0JB, Cohen\u00a0RM, Cushman\u00a0WC, et\u00a0al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"2189_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","volume":"6","author":"S Beddhu","year":"2018","unstructured":"Beddhu\u00a0S, Greene\u00a0T, Boucher\u00a0R, Cushman\u00a0WC, Wei\u00a0G, Stoddard\u00a0G, et\u00a0al. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol. 2018;6(7):555\u201363.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2189_CR36","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2337\/dc17-2443","volume":"41","author":"EYF Wan","year":"2018","unstructured":"Wan\u00a0EYF, Yu\u00a0EYT, Chin\u00a0WY, Fung\u00a0CSC, Fong\u00a0DYT, Choi\u00a0EPH, et al. Effect of achieved systolic blood pressure on cardiovascular outcomes in patients with type 2 diabetes: a population-based retrospective cohort study. Diabetes Care. 2018;41(6):1134\u201341.","journal-title":"Diabetes Care"},{"issue":"9118","key":"2189_CR37","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson\u00a0L, Zanchetti\u00a0A, Carruthers\u00a0SG, Dahl\u00f6f\u00a0B, Elmfeldt\u00a0D, Julius\u00a0S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351(9118):1755\u201362.","journal-title":"Lancet"},{"issue":"7160","key":"2189_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703\u201313.","journal-title":"BMJ"},{"issue":"24","key":"2189_CR39","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/eurheartj\/ehx809","volume":"39","author":"BA Bergmark","year":"2018","unstructured":"Bergmark\u00a0BA, Scirica\u00a0BM, Steg\u00a0PG, Fanola\u00a0CL, Gurmu\u00a0Y, Mosenzon\u00a0O, et\u00a0al. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. Eur Heart\u00a0J. 2018;39(24):2255\u201362.","journal-title":"Eur Heart J"},{"issue":"9638","key":"2189_CR40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann\u00a0JF, Schmieder\u00a0RE, McQueen\u00a0M, Dyal\u00a0L, Schumacher\u00a0H, Pogue\u00a0J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a\u00a0multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547\u201353.","journal-title":"Lancet"},{"issue":"1","key":"2189_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","volume":"59","author":"J Redon","year":"2012","unstructured":"Redon\u00a0J, Mancia\u00a0G, Sleight\u00a0P, Schumacher\u00a0H, Gao\u00a0P, Pogue\u00a0J, et\u00a0al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J\u00a0Am Coll Cardiol. 2012;59(1):74\u201383.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2189_CR42","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving\u00a0HH, Brenner\u00a0BM, McMurray\u00a0JJ, de Zeeuw\u00a0D, Haffner\u00a0SM, Solomon\u00a0SD, et\u00a0al. Cardiorenal end points in a\u00a0trial of aliskiren for type 2 diabetes. N\u00a0Engl J Med. 2012;367(23):2204\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"2189_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","volume":"56","author":"MA Weber","year":"2010","unstructured":"Weber\u00a0MA, Bakris\u00a0GL, Jamerson\u00a0K, Weir\u00a0M, Kjeldsen\u00a0SE, Devereux\u00a0RB, et\u00a0al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J\u00a0Am Coll Cardiol. 2010;56(1):77\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"2189_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-016-0391-8","volume":"15","author":"B Bohn","year":"2016","unstructured":"Bohn\u00a0B, Sch\u00f6fl\u00a0C, Zimmer\u00a0V, Hummel\u00a0M, Heise\u00a0N, Siegel\u00a0E, et al. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325\u00a0patients with type 2 diabetes: a\u00a0German\/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016;15:72.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2189_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jcjd.2017.01.005","volume":"42","author":"J Grenier","year":"2018","unstructured":"Grenier\u00a0J, Goodman\u00a0SG, Leiter\u00a0LA, Langer\u00a0A, Teoh\u00a0H, Bhatt\u00a0DL, et al. Blood pressure management in adults with type 2 diabetes: insights from the diabetes mellitus status in Canada (DM-SCAN) survey. Can J Diabetes. 2018;42(2):130\u20137.","journal-title":"Can J Diabetes"},{"issue":"23","key":"2189_CR46","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD, Pitt\u00a0B, Ruilope\u00a0LM, Rossing\u00a0P, et\u00a0al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N\u00a0Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"2189_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1524-6175.2005.04784.x","volume":"8","author":"R Qayyum","year":"2006","unstructured":"Qayyum\u00a0R, Adomaityte\u00a0J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J\u00a0Clin Hypertens (Greenwich). 2006;8(1):19\u201328.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"8","key":"2189_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang\u00a0B, Zhong\u00a0J, Lin\u00a0H, Zhao\u00a0Z, Yan\u00a0Z, He\u00a0H, et al. Blood pressure-lowering effects of GLP\u20111 receptor agonists exenatide and liraglutide: a\u00a0meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737\u201349.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2189_CR49","doi-asserted-by":"publisher","first-page":"e005686","DOI":"10.1161\/JAHA.117.005686","volume":"6","author":"WL Baker","year":"2017","unstructured":"Baker\u00a0WL, Buckley\u00a0LF, Kelly\u00a0MS, Bucheit\u00a0JD, Parod\u00a0ED, Brown\u00a0R, et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J\u00a0Am Heart Assoc. 2017;6(5):e5686. https:\/\/doi.org\/10.1161\/JAHA.117.005686.","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"2189_CR50","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, Wanner\u00a0C, Lachin\u00a0JM, Fitchett\u00a0D, Bluhmki\u00a0E, Hantel\u00a0S, et\u00a0al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N\u00a0Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"2189_CR51","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Mahaffey\u00a0KW, de Zeeuw\u00a0D, Fulcher\u00a0G, Erondu\u00a0N, et\u00a0al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2189_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott\u00a0SD, Raz\u00a0I, Bonaca\u00a0MP, Mosenzon\u00a0O, Kato\u00a0ET, Cahn\u00a0A, et\u00a0al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"2189_CR53","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00125-018-4547-9","volume":"61","author":"G Schernthaner","year":"2018","unstructured":"Schernthaner\u00a0G, Schernthaner-Reiter\u00a0MH. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia. 2018;61(7):1503\u201316.","journal-title":"Diabetologia"},{"issue":"14","key":"2189_CR54","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang\u00a0W, Zhang\u00a0S, Deng\u00a0Y, Wu\u00a0S, Ren\u00a0J, Sun\u00a0G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N\u00a0Engl J Med. 2021;385(14):1268\u201379.","journal-title":"N Engl J Med"},{"issue":"3s","key":"2189_CR55","first-page":"S1","volume":"99","author":"KDIGO","year":"2021","unstructured":"KDIGO. 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3s):S1\u2013s87.","journal-title":"Kidney Int"},{"issue":"1","key":"2189_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/HYPERTENSIONAHA.121.18434","volume":"79","author":"I Dasgupta","year":"2022","unstructured":"Dasgupta\u00a0I, Zoccali\u00a0C. Is the KDIGO systolic blood pressure target \u3008120\u202fmm Hg for chronic kidney disease appropriate in routine clinical practice? Hypertension. 2022;79(1):4\u201311.","journal-title":"Hypertension"},{"issue":"10","key":"2189_CR57","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1681\/ASN.2004110919","volume":"16","author":"MA Pohl","year":"2005","unstructured":"Pohl\u00a0MA, Blumenthal\u00a0S, Cordonnier\u00a0DJ, De Alvaro\u00a0F, Deferrari\u00a0G, Eisner\u00a0G, et\u00a0al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J\u00a0Am Soc Nephrol. 2005;16(10):3027\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2189_CR58","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller\u00a0H, Ito\u00a0S, Izzo\u00a0JL Jr., Januszewicz\u00a0A, Katayama\u00a0S, Menne\u00a0J, et\u00a0al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N\u00a0Engl J Med. 2011;364(10):907\u201317.","journal-title":"N Engl J Med"},{"issue":"11","key":"2189_CR59","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1097\/HJH.0000000000001548","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos\u00a0C, Parati\u00a0G, Zanchetti\u00a0A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. J\u00a0Hypertens. 2017;35(11):2138\u201349.","journal-title":"J Hypertens"},{"key":"2189_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijcard.2016.01.197","volume":"208","author":"XX Xie","year":"2016","unstructured":"Xie\u00a0XX, Liu\u00a0P, Wan\u00a0FY, Lin\u00a0SG, Zhong\u00a0WL, Yuan\u00a0ZK, et al. Blood pressure lowering and stroke events in type 2 diabetes: a network meta-analysis of randomized controlled trials. Int J Cardiol. 2016;208:141\u20136.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2189_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2008.03.002","volume":"202","author":"JA Dormandy","year":"2009","unstructured":"Dormandy\u00a0JA, Betteridge\u00a0DJ, Schernthaner\u00a0G, Pirags\u00a0V, Norgren\u00a0L. Impact of peripheral arterial disease in patients with diabetes\u2014results from PROactive (PROactive 11). Atherosclerosis. 2009;202(1):272\u201381.","journal-title":"Atherosclerosis"},{"issue":"2","key":"2189_CR62","doi-asserted-by":"publisher","first-page":"e002407","DOI":"10.1136\/bmjdrc-2021-002407","volume":"9","author":"L Sprenger","year":"2021","unstructured":"Sprenger\u00a0L, Mader\u00a0A, Larcher\u00a0B, M\u00e4chler\u00a0M, Vonbank\u00a0A, Zanolin-Purin\u00a0D, et al. Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease. BMJ Open Diabetes Res Care. 2021;9(2):e2407. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002407.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"2189_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","volume":"55","author":"AA Bavry","year":"2010","unstructured":"Bavry\u00a0AA, Anderson\u00a0RD, Gong\u00a0Y, Denardo\u00a0SJ, Cooper-Dehoff\u00a0RM, Handberg\u00a0EM, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR\/Trandolapril STudy. Hypertension. 2010;55(1):48\u201353.","journal-title":"Hypertension"},{"issue":"5","key":"2189_CR64","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.117.10713","volume":"71","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal\u00a0R, Steinkamp\u00a0J, Chiu\u00a0N, Petrie\u00a0B, Mirzan\u00a0H. Intensive blood pressure targets for diabetic and other high-risk populations: a pooled individual patient data analysis. Hypertension. 2018;71(5):833\u20139.","journal-title":"Hypertension"},{"issue":"5","key":"2189_CR65","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos\u00a0C, Parati\u00a0G, Zanchetti\u00a0A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10\u2014should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J\u00a0Hypertens. 2017;35(5):922\u201344.","journal-title":"J Hypertens"},{"issue":"10","key":"2189_CR66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41371-018-0079-5","volume":"32","author":"E Papadopoulou","year":"2018","unstructured":"Papadopoulou\u00a0E, Angeloudi\u00a0E, Karras\u00a0S, Sarafidis\u00a0P. The optimal blood pressure target in diabetes mellitus: a\u00a0quest coming to an end? J\u00a0Hum Hypertens. 2018;32(10):641\u201350.","journal-title":"J Hum Hypertens"},{"issue":"10285","key":"2189_CR67","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"The Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625\u201336.","journal-title":"Lancet"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02189-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02189-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02189-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T23:07:38Z","timestamp":1682550458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02189-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":67,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02189-1","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"3 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H.\u00a0Saely hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: MSD, AstraZeneca, Amgen, Sanofi-Aventis, Boehringer-Ingelheim, Novartis, Pfizer, Genericon, Takeda, Bayer. G.-H.\u00a0Schernthaner gibt an, dass kein Interessenkonflikt besteht. J.\u00a0Brix: Honorare f\u00fcr Advisory Boards und Vortr\u00e4ge von Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Novo Nordisk, Sanofi-Aventis. R.\u00a0Klauser-Braun hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, B\u00f6hringer Ingelheim, Kwizda, Menarini, Merck Sharp Dome, Novartis, Pfizer, Ratiopharm, Sanofi-Aventis, Servier, Takeda. E.\u00a0Zitt hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer-Ingelheim. H.\u00a0Drexel hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Bayer Austria, Boehringer-Ingelheim, Meda Pharma, Merck Sharp & Dohme, Novo Nordisk, sanofi-aventis, Servier. G.\u00a0Schernthaner gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}